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Abstract 36 
We have previously shown that prebiotics (dietary fibres that augment the growth of indigenous 37 
beneficial gut bacteria) such as BimunoTM galacto-oligosaccharides (B-GOS®), increased N-38 
methyl-D-aspartate (NMDA) receptor levels in the rat brain. The current investigation examined 39 
the functional correlates of these changes in B-GOS®-fed rats by measuring cortical neuronal 40 
responses to NMDA using in vivo NMDA micro-iontophoresis electrophysiology, and 41 
performance in the attentional set-shifting task. Adult male rats were supplemented with B-GOS® 42 
in the drinking water 3 weeks prior to in vivo iontophoresis or behavioural testing.  Cortical 43 
neuronal responses to NMDA iontophoresis, were greater (+30%) in B-GOS® administered rats 44 
compared to non-supplemented controls. The intake of B-GOS® also partially hindered the 45 
reduction of NMDA responses by the glycine site antagonist, HA-966. In the attentional set-46 
shifting task, B-GOS® -fed rats shifted from an intra-dimensional to an extra-dimensional set in 47 
fewer trials than controls, thereby indicating greater cognitive flexibility. An initial exploration 48 
into the mechanisms revealed that rats ingesting B-GOS® had increased levels of plasma acetate, 49 
and cortical GluN2B subunits and Acetyl Co-A Carboxylase mRNA. These changes were also 50 
observed in rats fed daily for 3 weeks with glyceryl triacetate, though unlike B-GOS®, cortical 51 
histone deacetylase (HDAC1, HDAC2) mRNAs were also increased which suggested an 52 
additional epigenetic action of direct acetate supplementation. Our data demonstrate that a pro-53 
cognitive effect of B-GOS® intake in rats is associated with an increase in cortical NMDA 54 
receptor function, but the role of circulating acetate derived from gut bacterial fermentation of this 55 
prebiotic requires further investigation. 56 
 57 
 58 
 59 
 60 
 61 
 62 
 63 
 64 
 65 
 66 
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1. Introduction 67 
 68 
The link between enteric microbiota and brain function is now widely accepted, has been 69 
considered as ‘a paradigm shift in neuroscience’ (Mayer et al, 2014). Mice depleted of microbiota 70 
(germ-free mice), display altered behaviours and reduced levels of Brain Derived Neurotrophic 71 
Factor (BDNF) and N-methyl-D-aspartate receptors (NMDARs), which are crucial for cognitive 72 
function (Sudo et al, 2004). Conversely, gut microbiota enrichment with specific probiotics, live 73 
beneficial bacteria, or prebiotics, indigestible compounds that augment the growth of intrinsic 74 
beneficial microbes, improve cognitive performance in rodents (Savignac et al, 2015; Vasquez et 75 
al, 2015; O’Hagan et al., 2017) and humans (Schmidt et al, 2015; Steenbergen et al, 2015). The 76 
reduction of attentional bias to negative emotional stimuli in healthy volunteers following a 77 
dietary supplementation with the BimunoTM galacto-oligosaccharide (B-GOS®) prebiotic (Schmidt 78 
et al, 2015), may be a corollary of increased levels of  NMDAR subunits which we have observed 79 
in the rat frontal cortex following B-GOS feeding (Savignac et al, 2013). However, the functional 80 
correlates of these changes have not been explored. 81 
 82 
The prebiotic properties of B-GOS® have been extensively studied, and the product which 83 
contains a mixture of galacto-oligosaccharides of several lengths (2-7 saccharides) has been 84 
consistently shown to selectively increase Bifidobacteria and, to some extent, Lactobacilli in both 85 
humans and animals (Tzortzis et al., 2005; Depeint et al., 2008; Vulevic et al., 2008; Silk et al., 86 
2009; Savignac et al., 2013). Understanding how B-GOS® modulates NMDARs has important 87 
implications for both the prevention of the age-related decline in cognitive function (Nicole and 88 
Baxter, 2003), and the treatment of neuropsychiatric disorders such as schizophrenia, where 89 
aberrant glutamate neurotransmission and cognitive deficits cannot be rescued by conventional 90 
medication. Given that the loss of NMDAR function impairs cellular responses in the rodent 91 
cortex (Rompala et al, 2013), we hypothesise that the elevated cortical GluN1 and D-serine 92 
following B-GOS® ingestion (Savignac et al, 2013), increases cortical NMDAR-mediated neural 93 
activity, and related behaviours. In the latter instance, based on existing data, increased cortical 94 
NMDAR function in healthy animals may improve attentional set-shifting performance (cognitive 95 
flexibility), a prefrontal cortex (PFC)-dependent behaviour often impaired by NMDAR 96 
antagonists (Neill et al, 2010; Wallace et al, 2014), or the natural decrease in cortical NMDAR 97 
levels during aging (Nicole and Baxter, 2003; Rodefer and Nguyen, 2008). However, there are no 98 
studies demonstrating improved cognitive flexibility in experimentally naïve rodents following an 99 
elevation of NMDARs, and/or their function, in the PFC. The increase of central NMDAR 100 
subunits in the rat brain following B-GOS ingestion, provides a model to test this. 101 
 102 
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There is also an urgent need to ascertain the mechanisms that underlie the central effects of B-103 
GOS®, so that key intermediaries of microbe-brain interactions can be revealed. The short-chain 104 
fatty acids (SCFAs) that arise from bacterial fermentation of dietary carbohydrates in the host gut, 105 
have been suggested to be one such mediator (Sarkar et al, 2016). Fermentation of B-GOS has 106 
been shown to produce significant amounts of acetate, and moderate amounts of butyrate 107 
(Grimaldi et al, 2016, 2017). Both of these SCFAs can have central effects, particularly at the 108 
epigenetic level where they both influence the expression of brain histone deacetylases (HDACs) 109 
(Soliman et al, 2012; Han et al, 2014), but a link between metabolic acetate and NMDARs has 110 
also been demonstrated (Hirose et al, 2009; Singh et al, 2016). In this regard, if acetate is involved 111 
in B-GOS® mediated changes of NMDAR function, then direct acetate supplementation might be 112 
expected to have similar effects on central NMDAR levels as the prebiotic itself.  113 
 114 
The aim of the current study was to, first, confirm with in vivo iontophoresis electrophysiology 115 
increased NMDAR function in the rat frontal cortex following B-GOS® intake alone, or in the 116 
presence of the NMDAR glycine-site antagonist, HA-966. Second, test if administration of B-117 
GOS® facilitated cognitive flexibility, based on the prebiotic-mediated elevation of cortical 118 
NMDARs. Third, explore the role of acetate in the actions of B-GOS® by (i) measuring plasma 119 
and brain levels of this SCFA in B-GOS® -fed and control rats, and (ii) quantifying in all animals 120 
the expression of frontal cortex Acetyl Co-enzyme A Carboxylase (ACC) mRNA. Earlier work 121 
has demonstrated that a single systemic injection of acetate into rats increases the activity of 122 
hypothalamic ACC (Frost et al, 2014).  This enzyme metabolises the Acetyl Co-enzyme A that is 123 
produced from the acetate sequestered in tissues. The abundance of cortical ACC mRNA 124 
therefore, was used as an indicator of acetate metabolism. In addition, the expression of HDAC(1-125 
4) genes in the cortex were measured to evaluate whether B-GOS®, via acetate, affects epigenetic 126 
processes. Finally, plasma and brain acetate, cortical GluN subunit levels, and ACC and HDAC(1-127 
4) mRNAs were evaluated in glyceryl triacetate fed rats to further examine the potential 128 
involvement of acetate in NMDAR modulation. 129 
 130 
2. Experimental Procedures 131 
2.1 Animals 132 
Adult male Sprague Dawley rats (250-300 g) were housed (3rats/cage) in standard laboratory 133 
conditions (21±1°C; lights on 07:00–19:00h), with free access to water and standard laboratory 134 
chow. For behavioural testing, rats had limited access to standard chow (food restricted) and 135 
maintained at 85–90% of their free-feeding weight throughout experiments. The nutritional 136 
content of the standard diet provided (Envigo, USA, product no. 2916) included protein (16%), fat 137 
(4%), crude fibre (3.3%), and insoluble fibre (eg cellulose, 15%).  All procedures were carried out 138 
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in accordance with UK Home Office Animals (Scientific Procedures) Act (1986) and associated 139 
Home Office guidelines. The procedures specific to this study were approved by the local Animal 140 
Welfare and Ethical Review Body (AWERB) at both DeMontfort and Oxford Universities.  141 
 142 
2.2 Prebiotic Administration 143 
Rats received normal drinking water, drinking water supplemented with 3% B-GOS®, or drinking 144 
water supplemented with B-GOS® free sugars (BFS: lactose [7.5 g/L], glucose [4.2 g/L] and 145 
galactose [3.6g/L]) for 3 weeks and throughout behavioural tests. The inclusion of a BFS group 146 
was to determine whether any behavioural effects of B-GOS® was attributable to the ingestion of 147 
the sugars in the prebiotic mixture, rather than the galato-oligosaccharides. Body weight and fluid 148 
intake in all groups were recorded every 2 days. Food restriction for behavioural studies 149 
commenced 7 days after the provision of prebiotic. 150 
 151 
2.3 Glyceryl Triacetate Administration 152 
In a separate study male rats (250-300g) were gavaged with glyceryl triacetate (GTA, 1g/ml, 153 
Sigma Aldrich, UK) at a final dose of 3g/kg, or the same volume of water alone (control) daily for 154 
3 weeks. The choice of GTA dose and control was based on a previous studies (Singh et al, 2016). 155 
 156 
2.4 In vivo Iontophoresis Electrophysiology 157 
These experiments were conducted on B-GOS®-fed rats and water controls as previously 158 
described (Di Miceli and Gronier, 2015). Animals were deeply anaesthetised with urethane (1.2–159 
1.7 g/kg, intraperitoneal, with additional doses if necessary), secured to a stereotaxic frame and 160 
maintained at 36–37 °C. Briefly, under urethane anaesthesia, animals underwent stereotaxic 161 
surgery to drill a hole in the skull over the PFC (co-ordinates from Bregma: anteroposterior + 2.5–162 
3.7mm, lateral 0.3–2mm). Five-barrel glass micropipettes (ASI, USA), pulled on a PP-830 163 
electrode puller (Narishige, Japan) were used. The central barrel, filled with a saline solution, was 164 
used for recording, and the four-side barrels were filled with at least one of the following 165 
solutions: NMDA (30 mM in 200 mM of NaCl, pH 7.5), HA-966 (10 mM, in 200 mM NaCl, pH 166 
4) and 1 M NaCl for current balancing (later found to be unnecessary).  167 
 168 
Outputs from the electrode were sent to a Neurolog AC pre-amplifier and amplifier (Digitimer, 169 
UK). Signals were filtered and sent to an audio amplifier, a digital storage oscilloscope and a 1401 170 
interface connected to a computer running Spike 2 (CED, Cambridge, UK) for data capture and 171 
analysis. Descent of the electrode was accomplished using a hydraulic micromanipulator 172 
(Narishige). Coordinates for the PFC were as follows: anteroposterior 2.5–3.7 mm, lateral 0.3–2 173 
mm, 1.5–5 mm below cortical surface. Neurons were identified according to previous 174 
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electrophysiological criteria established from studies carried on formally identified pyramidal 175 
neurons (Hajos et al, 2003; Puig et al, 2005; Tseng et al, 2006; Kargieman et al, 2007; Gronier et 176 
al, 201; Wang et al, 2011): a broad action potential (>1 ms), with a biphasic or triphasic, large 177 
waveform, starting with a positive inflection, a slow firing rate typically between 1 and 50 178 
spikes/10 s and irregular firing pattern, often with burst activity. 179 
 180 
Neuronal response was measured by the software (Spike 2, Cambridge Electronic design) as 181 
actions potentials (number of spikes) generated both at baseline and in response to drugs 182 
injections, from a neuron per 10 seconds.  All data were expressed as a net response relative to 183 
baseline recordings. NMDA or AMPA were ejected as cations by applying a negative current at a 184 
given intensity (-1-15 nA) for 40-70 s at 70-100 s interval. HA-966 was ejected as an anion by 185 
applying a positive current (-3-35 nA) during a long-lasting stable (>200 s) neuronal activation 186 
elicited by NMDA or AMPA application. Drugs were retained in the iontophoretic channel by 187 
applying a low intensity current (2-5 Na) of opposite charge of the ejection current. 188 
 189 
2.5 Attentional Set-Shifting Task (ASST) 190 
This task was carried out on B-GOS® supplemented rats and water controls using an established 191 
procedure (Burnham et al, 2010). The testing chamber was a home cage with Perspex dividers 192 
separating the cage into a start chamber and two identically sized choice chambers with access 193 
controlled by Perspex doors. Ceramic bowls were placed within the choice chambers and baited 194 
with pieces of sweetened cereal (Honey Nut Cheerios, Nestle, Surrey, UK). A piece of cereal was 195 
also placed at the bottom of each bowl to mask the odour of the bait, and was protected by a fixed 196 
wire mesh to make it inaccessible to rats. During testing, one bowl was baited and rats 197 
discriminated the baited bowl using the texture and/or the odour of the digging medium. Choice 198 
was defined as active digging or foraging with the snout in the digging medium. Rats were 199 
habituated to the apparatus and initially taught to dig in baited bowls filled with home cage 200 
bedding. On the day prior to testing, rats performed two simple discriminations, one based on 201 
odour (lavender versus lemon scented bedding) and one based on medium (small wooden beads 202 
versus large wooden beads), to a criterion of six consecutive correct trials. The order of training 203 
discriminations (odour/medium) and the rewarded odour and digging medium were counter-204 
balanced, and exemplars (Table 1) were not used again throughout testing. 205 
 206 
All the discriminations in the testing sequence were presented in a single test day. The first four 207 
trials of each discrimination were “discovery” trials, during which the rat was allowed to dig in 208 
medium both bowls, to discover which bowl contained the reward. An error was recorded if the rat 209 
dug first in the unbaited bowl, but these trials were not included in the trials or errors to criterion 210 
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score. After the first four trials, if the rat dug in the unbaited bowl, an error was recorded and 211 
access to the correct bowl was denied. The rat was allowed to return to the start chamber of its 212 
own accord to start the next trial. Testing continued until the rat reached a criterion of six correct 213 
consecutive trials. The sequence and composition of several discriminations used in the test are 214 
summarized in Table 1. A simple discrimination (SD), between either two odours or two digging 215 
mediums, was followed by a compound discrimination (CD) which had the same positive stimulus 216 
as the SD, but included a new irrelevant dimension which did not predict the location of the 217 
reward. This was followed a reversal of the CD (R1) where all of the stimuli remained the same, 218 
and the relevant dimension remained the same,  but the rewarded and non-rewarded stimuli within 219 
the dimension were reversed. The rats were then subjected to an Intra-dimensional (ID) shift 220 
which was a CD in which both the relevant and irrelevant stimuli changed, but the rewarded 221 
dimension (either odour or medium) remained the same. This was followed by a second reversal 222 
(R2) stage as described for R1.  The rats were then exposed to an extra-dimensional (ED) shift, 223 
where the relevant and irrelevant stimuli changed, as well as the relevant dimension, so if odour 224 
had previously predicted the location of the reward, the digging would become the relevant 225 
dimension. A third reversal (R3) followed the ED, as described for R1 and R2. The experimenter 226 
was blind to treatment and remained in the experimental room silently during experiments for live 227 
scoring. Animals were tested in a controlled, random fashion regarding cage and treatment groups, 228 
and then were returned to their home cage where provision of prebiotic or control solutions 229 
continued. All rats were humanely culled 24 hrs after behavioural testing. 230 
 231 
2.6 Blood and Tissue Collection 232 
On completion of all experiments rats were culled and the trunk blood collected in sterile 2ml 233 
heparin-coated Eppendorf tubes. Samples were centrifuged for 5min in a bench-top centrifuge at 234 
maximum speed, the plasma was removed and stored at -80oC prior to acetate assays. The frontal 235 
cortex was cut from cerebrum, bisected and stored at -80oC prior to use. Faecal pellets were also 236 
collected from all rats that had been subjected to the ASST, and frozen at -80oC prior to DNA 237 
extraction. 238 
2.7 Western Blotting 239 
One hemisphere of the frontal cortex from each group of rats was homogenised in RIPA buffer 240 
(Sigma-Aldrich, UK), and run on western blots as previously described (Savignac et al, 2013). 241 
Equal concentrations of protein extracts of the cortex (10ug) from all groups (n=8 rats/group) were 242 
mixed with loading buffer (50mM 1, 4-dithiothreitol and 0.025% bromophenol blue), and 243 
fractionated with a molecular weight marker (GE Healthcare, Buckinghamshire, UK) by 244 
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electrophoresis on pre-cast 7.5% SDS/polyacrylamide gels (Biorad,UK), and trans-blotted onto 245 
polyvinyl difluoride (PVDF) membranes (Immobilon-P, Millipore, Watford, UK).  246 
The membranes were blocked with 5% (w/v) non-fat milk in PBS containing 0.1% Tween20 247 
(PBST) for 45min, and then incubated for 1 h at room temperature in incubation buffer (PBST 248 
with 2% [w/v] milk) containing a primary antibody (diluted 1:1000) against one of three NMDAR 249 
subunits: GluN1 (AB9864, Millipore, UK), GluN2A (AB1555, Millipore, UK) and GluN2B 250 
(AB15362, Millipore, UK), and β-actin (Sigma-Aldrich, UK, diluted 1:500,000). Membranes 251 
were then washed three times for ten minutes in PBST and incubated for 30min in HRP-linked 252 
secondary antibody in blocking buffer. Immunoreactive bands were visualized by 253 
chemiluminescence using the ECL-Plus kit (GE Healthcare, Buckinghamshire, UK), and apposing 254 
membranes to X-ray film (Kodak BioMax AR film). All antibodies produced a single band of 255 
expected molecular weight. The optical densities (OD) of bands were measured using the 256 
AlphaImager 3400, and the data expressed as OD ratios of NMDAR subunit:β-actin. 257 
 258 
2.8 Extraction of Cortical RNA and Faecal DNA, and quantitative PCR (QPCR) 259 
Total RNA was extracted from the remaining fragment of cortical tissue using Tri-Reagent 260 
according to manufacturer’s instructions, and reverse-transcribed to cDNA, using a commercial 261 
kit (Life Technologies, UK). The SYBR Green methodology (Power SYBER, Life Technologies, 262 
UK) was applied to amplify mRNA encoding Acetyl Co-Enzyme-A Carboxylase (ACC) in all 263 
cortical cDNA preparations using previously published primers.  264 
Bacteria DNA from faecal samples was extracted using QIAamp DNA Stool Mini Kit (Qiagen, 265 
Hilden, Germany) after mechanical disruption. The abundance of 16S DNA encoding specific 266 
microbial genera and total bacteria in faecal pellets were analysed using qPCR and previously 267 
published primers (Morel et al., 2014). The SYBR Green methodology was used to amplify 20ng 268 
DNA. All QPCR assays were performed on a 7900HT Fast Real-Time PCR System (Applied 269 
Biosystems, USA). 270 
 271 
2.9 Acetate Assay 272 
The concentration of acetate in plasma and cortical homogenates were measured using a 273 
commercial colorimetric assay (ab204719, Abcam, UK).  Prior to all assays, plasma and RIPA 274 
extracts of frontal cortex (see above) were thawed and 50ul were aliquoted into1.5ml Eppendorf 275 
tubes. An equal volume of isopropanol was then added to all samples and thoroughly mixed to 276 
precipitate proteins. Tubes were centrifuged on a bench-top centrifuge for 5 min at maximum 277 
speed, and the supernatant was transferred to a fresh tube. All samples were dried down and the 278 
anhydrous metabolites dissolved in 50ul acetate buffer. Ten microliters of protein-free plasma and 279 
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cortical extracts were assayed for acetate in duplicate with a standard curve according to 280 
manufacturer’s instructions. 281 
 282 
 283 
2.10 Data Analysis 284 
Normal distribution of data was confirmed using Shapiro-Wilk test (SPSS, ver.22). All data are 285 
expressed as mean + standard error of the mean (SEM). Electrophysiological, behavioural body 286 
weight and fluid intake data were analysed with Two-way ANOVA (repeated measures), and 287 
Bonferroni post-hoc correction. All QPCR data are presented as fold change (relative to GAPDH 288 
for tissue, and total bacterial 16S for faecal DNA) which were calculated using the 2-∆∆Ct relative 289 
quantitation method (Livak and Schmittgen, 2001). Acetate concentrations were also calculated as 290 
fold-change relative to control group (experimental or control value/mean control value) so that 291 
plasma and brain acetate changes could be compared to brain ACC levels. All western blot OD 292 
ratios, and QPCR and acetate fold changes were analysed using one way ANOVA and Tukey 293 
post-hoc tests.  294 
 295 
3. Results 296 
3.1 Effect of B-GOS® Intake on Cortical NMDA Responses 297 
In the first iontophoresis experiment, a total of 36 and 44 neurons in the control and B-GOS® 298 
groups, respectively, were included (6-10 neurons per rat tested). All neurons tested exhibited the 299 
electrophysiological characteristics of pyramidal neurons according to pre-determined criteria (see 300 
above). Neurons from both B-GOS® and water groups had similar low basal firing activity (12.6 ± 301 
2.6 and 7.7 ± 1.2 Spikes/10 s for B-GOS® and water groups, respectively, p>0.05), and more than 302 
60% of the tested neurons from both groups had virtually no basal firing activity (firing rate <4 303 
spikes/10 s). Iontophoretic application of NMDA, applied at currents between -5-10 nA, (Fig1A) 304 
produced a current dependent increase in firing activity, from baseline levels by 10-30 additional 305 
spikes/10 s per 5nA of NMDA applied. However, the response plateaued at the highest current 306 
tested (-15 nA), being only slightly higher than the response obtained at -10 nA. This effect is 307 
probably due to saturation of NMDA receptors and/or partial depolarisation-inactivation, as some 308 
neurons tend to depolarise when currents higher than -10 nA were applied. Only neurons which 309 
produced consistent neuronal activations at a given current over time were selected. At all currents 310 
tested, the mean neuronal responses to iontophoretic NMDA in the PFC were greater in B-GOS® -311 
fed rats relative to controls (F1,78=7.01, p=0.011) (Fig1B). There was no diet x current (NMDA) 312 
interaction (F2, 156 = 0.99, p>0.05).  313 
 314 
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In another experiment, the ability of the NMDAR glycine site antagonist, HA-966, to reduce the 315 
response of neurons to NMDA was tested. A long lasting application of NMDA (>10 min) at low 316 
currents (-5-10 nA), was sufficient to produce a stable level of mild activation (40-75 spikes/10 s) 317 
during which HA-966 was applied at various currents at 30-50 s intervals (Fig. 2). The 318 
iontophoretic application of HA-966 to cortical neurons inhibited NMDA-mediated responses at 319 
all currents tested (-5-25nA), in a current-dependent manner in both B-GOS® and control animals 320 
(Fig 2A). A diet x current (HA-966) interaction was not observed (F3,90 =1.15, p>0.05), although 321 
there was an effect of group (F1,30=4.91, p=0.037). This was driven by the greater magnitude of 322 
the NMDA-mediated response in B-GOS® rats at -25nA HA-966 compared to controls (p=0.013) 323 
(Fig2B). These data when plotted as % Response, (net response with HA-966/net response no HA-324 
966 *100), confirmed that B-GOS®  reduced responses at -25nA without shifting the inhibitory 325 
dose response curve relative to the water group (Fig2C).  326 
To test whether HA-966 interacted with sites other than the NMDAR glycine binding site, neurons 327 
were exposed to the inhibitor in the absence of NMDA stimulation (Fig 3). Histograms in Fig3A 328 
show that HA-966 applied at -15nA did not affect baseline responses. The uninterrupted 329 
administration of NMDA before and after HA-966 application, revealed full recovery of the 330 
NMDA response after the cessation of antagonist application, and so confirmed that the selected 331 
neurons were fully responsive to NMDAR stimulation and that this response was sensitive to HA-332 
966. Although neurons were also responsive to AMPA, AMPA-dependent activity was not 333 
blocked by HA-966 (Fig 3B). This lack of effect of HA-966 toward AMPA-induced activity 334 
verified the specificity of the effect of HA-966 for NMDAR. 335 
 336 
3.2 Effect of B-GOS on ASST Performance, Body weights, Fluid Intake and Faecal 337 
Bifidobacterium Spp. 338 
The administration of B-GOS® improved ID/ED set shifting in the ASST paradigm, whereas rats 339 
provided with BFS performed worse than rats provided with normal drinking water (Fig 4A). A 340 
significant diet x discrimination interaction (F12,162 = 4.43, p=0.001) was observed which was 341 
attributable to the effect of both B-GOS® and BFS on ED performance relative to controls 342 
(F2,27=24.78, p<0.001). Post hoc analysis with Bonferroni correction revealed that B-GOS® -fed 343 
rats required fewer trials to reach criterion in the ED discrimination task compared to controls 344 
(p=0.003), whereas the BFS supplemented rats required significantly more trials to reach criteria 345 
in the ED phase compared to both control (p=0.048) and B-GOS® (p<0.001) animals. A 346 
significant difference between ID and ED performance in control (F1,24 = 30.49, p<0.001) and BFS 347 
(F1,24 = 83.91, p<0.001) groups was not observed for B-GOS® rats (F1,24 = 2.03, p>0.1), and 348 
indicated improved ID/ED set-shifting, thus cognitive flexibility, in these animals.  349 
 350 
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The analysis of average changes in body weight throughout the supplementations and duration of 351 
the behavioural experiments did not reveal a diet x weight x time interaction, but showed a 352 
significant effect of diet (F50,702 = 49.04, p<0.001). This was driven by the elevation of body 353 
weight in BFS rats relative to controls (p<0.01) primarily on days 34-50, following food 354 
deprivation for ASST experiments (Fig 4B). No significant differences in body weight were 355 
observed between controls and B-GOS® rats (p>0.05). The analysis of fluid intake also revealed a 356 
significant effect of group (F50,702 = 173.98, p<0.001), which was attributed to the BFS rats 357 
drinking significantly more than controls (p<0.001) from days 4-50 (Fig4C). The intake of B-358 
GOS® supplemented water was not different to the consumption of water alone (p>0.05). 359 
 360 
The QPCR analysis of Bifidobacterium Spp. in faecal DNA from rats subjected to ASST revealed 361 
a significant difference between groups (F2,21 = 5.043, p=0.021). The fold-change in bacteria in the 362 
B-GOS fed animals was approximately two-fold greater than the other groups (Means + SEM of 363 
Water = 0.99 + 0.36; BFS= 0.90 + 0.30; B-GOS® = 2.45 + 0.47; p<0.05, Water vs B-GOS® and 364 
BFS vs B-GOS® groups). 365 
 366 
3.3 Effects of B-GOS® or GTA supplementation on GluN Subunits, Plasma and Cortical 367 
Acetate, and Cortical ACC, HDAC1 and HDAC2 mRNAs. 368 
Western blot analysis of cortical tissue from rats (Fig 5A) demonstrated a significant elevation of 369 
GluN2B in the B-GOS® group compared to controls (F1,20 =  6.13, p=0.036). To explore the 370 
possibility that increased circulating acetate could influence NMDAR subunit expression, GluN 371 
subunits were measured in rats gavaged daily with GTA for 3 weeks. A significant increase of 372 
cortical GluN1 (F1,20 =  8.32, p=0.018), and GluN2B (F1,20 =  6.32, p=0.033) subunits were 373 
observed in GTA fed rats compared to controls, (Fig 5B) 374 
 375 
Plasma acetate concentrations (F1,20 = 6.98, p=0.019) and the abundance of cortical ACC mRNA 376 
(F1,20 = 6.7, p=0.021), were also elevated by B-GOS® supplementation, (Fig 5C). The levels of 377 
cortical acetate did not alter with B-GOS® feeding relative to controls. Similarly, cortical ACC 378 
mRNA abundance increased (F1,20 = 8.83, p=0.01), following GTA supplementation, and this was 379 
paralleled by an approximately 3-fold elevation of plasma acetate levels (F1,20 =13.24, p=0.006),  380 
(Fig5D). No changes in cortical acetate levels were observed in these rats. 381 
 382 
The intake of B-GOS® for 3 weeks did not affect HDAC (1-4) gene expression in the frontal 383 
cortex (Fig6A). However, GTA administration elevated both HDAC1 (F1,20 = 5.01, p=0.049) and 384 
HDAC2 (F1,20 = 5.09, p=0.048) mRNAs (Fig6B). Cortical HDAC3 and HDAC4 mRNA 385 
abundance remained unaltered following GTA supplementation. 386 
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 387 
4. Discussion 388 
 389 
Maintaining healthy cognitive function has become one of the major challenges, both for 390 
neuropsychiatric disorders and healthy ageing in which optimal activity of the NMDAR is crucial. 391 
We have previously demonstrated that B-GOS® intake by adult rats elevated cortical GluN1 392 
subunits and its co-agonist, D-serine (Savignac et al, 2013). The current study investigated the 393 
functional correlates of these alterations by measuring cortical NMDAR responses and cognitive 394 
flexibility in B-GOS®  fed rats, and found increased neuronal responses to iontophoretically 395 
applied NMDA, and improved ID/ED set shifting in B-GOS®  supplemented animals compared to 396 
controls. Additional experiments suggest that acetate, a metabolite of B-GOS® fermentation, 397 
might be involved in the elevation of NMDAR subunits following prebiotic intake. Overall, these 398 
data confirm that B-GOS® influences NMDAR function, though the interpretation some specific 399 
findings require careful consideration. 400 
 401 
The increased magnitude of NMDA-mediated responses following B-GOS® intake compared to 402 
controls in the PFC, suggests elevated cortical NMDAR function. Our current observations, 403 
therefore, are in-keeping with our previous finding of increased GluN1 subunits in the cortex of B-404 
GOS®-fed rats (Savignac et al, 2013). Since in that study, B-GOS® feeding also elevated cortical 405 
D-serine, and in other work increased synaptic concentrations of NMDAR co-agonists hindered 406 
the dampening effects of HA-966 on NMDAR activity in rats (Chen et al, 2003), we tested if B-407 
GOS supplementation attenuated HA-966 blockade. The lack of a B-GOS® x HA-966 interaction, 408 
indicated that the antagonist reduced the NMDA-evoked responses in both controls and B-GOS®-409 
fed rats, and suggests that prebiotic supplementation did not hinder HA-966 binding to the 410 
NMDAR. However, B-GOS® did influence the magnitude of the NMDA response at the highest 411 
concentration of HA-966 (25nA, Fig2B), relative to controls. Plotting these data as an inhibition 412 
dose response curve (Fig 2C) not only confirmed the significant B-GOS® effect at the highest 413 
concentration of inhibitor, but also revealed that both the prebiotic and control inhibition curves 414 
overlapped at the lower HA-966 concentrations. This argues against additional populations of 415 
GluN1 subunits or higher D-serine levels following B-GOS® intake in the present investigation. 416 
 417 
Increased levels of GluN1 subunits and/or D-serine relative to controls would be expected to cause 418 
a right-ward shift in the HA-966 inhibitory curve because, higher concentrations of the antagonists 419 
would be required to occupy the additional subunits and/or compete with higher synaptic 420 
concentrations of D-serine, and since this was absent after B-GOS® intake the elevation of cortical 421 
GluN1 subunits (or D-serine) in this study can be ruled out. Indeed, western blots of rat cortical 422 
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tissues revealed that the B-GOS® administration increased GluN2B subunits compared to controls 423 
(Fig 5A). This suggests elevated NMDAR function via increased GluN2B-containing populations 424 
of receptors and may explain a group difference at the highest HA-966 concentration. That is, 425 
lower concentrations of HA-966 may have been blocking a majority of NMDARs comprising of 426 
GluN2A subunits which are also abundant in the cortex, but when these became saturated the 427 
observed NMDA responses arose from the GluN2B containing receptors, which have different 428 
(slower) functional kinetics to the GluN2A moieties (Monaco et al, 2015). Of course, the 429 
differential responses between B-GOS® and control groups may also suggest that the high 430 
antagonist concentrations might be binding to extraneous non-NMDAR sites. However, the 431 
demonstration that neither HA-966 alone nor in the presence of other excitatory stimuli (AMPA, 432 
Fig 3) influence neuronal responses, confirms that the inhibitor was only targeting NMDARs.  433 
Future work into the mechanisms of B-GOS® central actions might explore the involvement of 434 
other neurotransmitter systems such as GABA, which have been implicated in both the mediation 435 
of microbiome-gut-brain communication (Sarkar et al., 2016) and the modulation of cortical 436 
neural activity (Puig et al, 2005). 437 
 438 
It is clear from the current electrophysiological experiments that B-GOS® ingestion elevates 439 
cortical NMDAR function in rats, and from our previous studies, this does not seem to be 440 
mediated by changes in the concentration of peripheral or central glutamate itself (Savignac et al., 441 
2013). However, the initial changes on which our present hypothesis was based ie elevated 442 
cortical GluN1, was not observed. One possible explanation is the method of prebiotic 443 
administration where in our original experiments rats were gavaged, but in the present study B-444 
GOS® was provided via their drinking water. The gavage technique is known to be stressful 445 
(Gonzales et al, 2014), and although control animals received the same manipulation in our earlier 446 
investigation, the procedure may have affected pre-existing levels of NMDAR subunits. The 447 
expression of total GluN1 is significantly reduced by stress (Yuen et al, 2012) and so if this 448 
occurred in our first study (Savignac et al, 2013) and B-GOS® attenuated this effect, it would have 449 
been observed as an increase in these subunits relative to controls. This of course is speculative 450 
and the possibility that specific prebiotic feeding regimens lead to differential neurobiological 451 
outcomes would require further investigation. 452 
 453 
Our data provide further evidence for the cognitive-enhancing effects of a non-pharmacological 454 
intervention that is known to proliferate beneficial gut bacteria (see also Burokas et al., 2017).  455 
The improvement in attentional set-shifting is consistent with our demonstration of improved 456 
attentional vigilance in healthy volunteers supplemented with B-GOS® (Schmidt et al, 2015), and 457 
suggests that the prebiotic has a significant influence on cortical-mediated processes. Other 458 
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evidence for the influence of beneficial gut bacteria on cortical function and cognitive processes 459 
has also been provided by some probiotic studies (Steenbergen et al, 2015; Tillisch et al, 2013; 460 
Carlson et al., 2017). We have also considered how the sugar content of B-GOS® may have 461 
influenced behaviour. Studies subjecting rodents to tests of hippocampal function have reported 462 
poor spatial memory following a daily, 4 week administration of a 10% sucrose solution which 463 
also increased fluid intake (Kendig et al, 2013). Since the B-GOS® solution provided to the rats 464 
contained only 0.42% glucose (or 1.53% of total sugars, see Experimental procedures), it seems 465 
unlikely that the intake of the sugars in the B-GOS® formulation would influence behaviour at all.  466 
However, it is clear from our behavioural experiments that B-GOS® sugars (BFS) impaired 467 
performance on the attentional set-shifting task (Fig4A).  In this instance, the increased fluid 468 
intake with BFS, probably due to increased palatability of the solution in the absence of 469 
oligosaccharides, may have induced satiety and impaired the drive to find the food reward. 470 
Whatever the reason, it would appear that BFS is not an appropriate control for B-GOS® when 471 
provided in the drinking water.   472 
 473 
The B-GOS® induced augmentation of cortical NMDAR electrophysiological responses, and 474 
improved set-shifting performance, provides further compelling evidence for the influence of 475 
supplements that proliferate beneficial gut bacteria, on central glutamate neurotransmission and 476 
their pro-cognitive effects. A deficit in attentional set-shifting abilities (behavioural responses to 477 
changes in environmental cues), is observed in schizophrenia (Pantelis et al, 2009), a disorder that 478 
has been associated with NMDAR hypofunction. In rats, the central NMDAR has been shown to 479 
be crucial for normal ASST performance, since its pharmacological blockade (Neill et al, 2010) or 480 
age-related reduction in the brain (Nicole and Baxter, 2003), hinders an animal’s capacity to 481 
readily shift between two dimensions in the discrimination task. Improved ID/ED set-shifting in 482 
experimental models of NMDAR-impairment, has been achieved with nicotinic acetylcholine 483 
receptor agonists (Wood et al, 2016), or an opioid antagonist Wallace et al, 2014), but the direct 484 
influence of increased NMDAR function on ASST performance in healthy rats has not been 485 
reported.  486 
 487 
The next part of the study was to test the theory that the SCFA, acetate, a major microbial 488 
metabolite of B-GOS® (Grimaldi et al, 2016), is involved in the modulation of cortical NMDAR 489 
levels. This was based on a recent report showing that acetate supplementation attenuated the 490 
molecular effects of NMDAR blockade by MK801 (Singh et al, 2016). We have demonstrated for 491 
the first time that B-GOS® supplementation elevated circulating acetate concentrations and the 492 
cortical expression of ACC mRNA, which parallels the observed changes in these parameters 493 
following GTA administration. Importantly, since both interventions also elevated cortical 494 
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GluN2B levels it is very plausible that acetate is a mediator of the psychotropic actions of B-495 
GOS®. The additional elevation of GluN1 after GTA feeding, albeit also observed after B-GOS® 496 
in an earlier study (Savignac et al, 2013), may either be related to the method of administration as 497 
discussed above, and/or the relatively greater levels of acetate arising from its direct 498 
administration. The latter possibility may also explain the differential effects of B-GOS® and GTA 499 
on the expression of brain HDACs, but the key implication of these data is that epigenetic changes 500 
are not essential for B-GOS®-mediated central effects.  501 
 502 
Acetate supplementation has been shown to elevate brain levels of Acetyl-CoA (Bhatt et al, 2013) 503 
and may have been the cause of elevated ACC gene expression following B-GOS® and GTA 504 
intake ie increased ACC is a homeostatic response to normalize levels of its substrate generated 505 
from free acetate. However, the concentration of brain acetate is also modulated by its uptake, 506 
which can be hindered by NMDARs (Hirose et al, 2009). Therefore, our observed elevation of 507 
cortical GluN2B levels and NMDAR function after B-GOS® feeding could also be interpreted as a 508 
homeostatic response to elevated circulating acetate. Thus, the reduced uptake of acetate through 509 
elevated NMDAR activity together with increased levels of ACC might explain the unaltered 510 
levels of brain acetate after B-GOS® (Fig 5B) or GTA (Fig 5D).   511 
 512 
Indirect evidence for increased central metabolism underlying the actions of B-GOS® on the brain 513 
was the finding that HDAC gene expression remained unaltered after prebiotic feeding, which 514 
excluded the involvement of acetate-mediated epigenetic effects. We have confirmed the elevation 515 
of HDAC1 and HDAC2 following GTA (Soliman et al, 2012, and see Fig 6) at the level of 516 
encoding mRNA which supports data showing that direct acetate supplementation does influence 517 
central epigenetic pathways. It is noteworthy that GTA-mediated attenuation of MK801 effects, 518 
involved increased brain histone acetylation and activation of NMDAR-independent signalling.  519 
Our current finding may indicate, therefore, that circulating acetate levels following B-GOS®  520 
ingestion activate NMDAR mediated processes whereas the higher concentrations that arise from 521 
GTA supplementation, trigger additional epigenetic processes. This interpretation of our findings 522 
would require testing by performing GTA dose response experiments and measuring NMDAR 523 
function and brain histone acetylation. Furthermore, changes in HDAC activity would also be 524 
important to assess since this may alter independently of encoding mRNA eg via post-translational 525 
phosphorylation (Singh et al, 2016).  526 
 527 
It should be emphasized that this study only focussed on the involvement of acetate because it is a 528 
major metabolite of B-GOS® and has been linked to NMDARs (Hirose et al, 2009; Singh et al, 529 
2016). Moreover, the detection of circulating acetate is easily achieved using rapid, commercially 530 
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available kits that can be used for subsequent human trials. Of course, acetate is not the only 531 
SCFA that results from microbial fermentation of B-GOS®. Increased enteric butyric acid 532 
following B-GOS® intake (Grimaldi et al, 2016, 2017) has significant effects on the gut epithelium 533 
and may influence central functions via the established routes (eg immunity) of the gut-brain axis 534 
(Stilling et al, 2016). Moreover, butyrate directly affects central gene expression via epigenetic 535 
mechanisms (Han et al, 2014; Stilling et al, 2016). Thus, the effect of this SCFA on brain HDAC 536 
activity/protein phosphorylation status following the administration of butyrate would have to be 537 
analysed to completely rule out the role of this metabolite in the central actions of B-GOS®.  538 
Finally, it is important to note that a recent study using another formulation of GOS and in 539 
combination with a fructo-oligosaccharide (FOS), demonstrated psychotropic effects but did not 540 
reveal an association between acetate levels and NMDAR subunits in the hippocampus (Burokas 541 
et al, 2017). In the light of our present data, this may suggest that acetate may have region specific 542 
effects. However, the study also demonstrated a reduction of Bifidibacteria and Lactobacilli with 543 
the FOS and GOS formulations whereas we have reported the increase in the former with B-GOS® 544 
(Savignac et al, 2013, 2016); this indicates that even the primary actions of these prebiotics are 545 
different. Of course, it would be naïve to conclude that the modulation of brain function solely 546 
depends on changes in the levels of just two genera of bacteria given the vastness of the gut 547 
microbiome, but the discrepancies do emphasise that our findings with B-GOS® are only 548 
applicable to this specific prebiotic mixture, and cannot be extended to all formulations of GOS. 549 
The current study used B-GOS® because it is readily available to the consumer (BimunoTM, for 550 
composition see Vulevic et al, 2008), and its bifidogenic actions in animals and humans have been 551 
well documented (see above). Future mechanistic and functional studies with other prebiotics 552 
therefore, will need to consider not only animal species and appropriateness of tests for different 553 
brain regions, but also the formulation and principal effect of the compound under investigation. 554 
 555 
In conclusion, the current study provides an original demonstration of elevated cortical NMDAR 556 
responses and improved cognitive flexibility following B-GOS® intake. A potential mechanism 557 
has also been proposed where increased circulating acetate that results from B-GOS® metabolism 558 
may affect NMDAR neurobiology via metabolic pathways rather than through direct influences on 559 
epigenetic mechanisms that modulate gene expression. Supplementing rats directly with acetate 560 
provided this initial proof-of-concept, but additional experiments are required to confirm whether 561 
changes in NMDAR subunit levels after GTA have similar functional actions as B-GOS® feeding. 562 
One important implication of our findings is that the ingestion of B-GOS® in adulthood may offer 563 
‘neuroprotection’ and limit age-related deterioration of NMDAR and cognitive function. Another 564 
possibility is that B-GOS® might be used as an adjunctive therapy in neuropsychiatric disorders 565 
such as schizophrenia, depression, or dementia, where cognitive deficits are a prominent feature of 566 
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these illnesses, and do not respond to current treatments. Human trials are therefore required to 567 
validate these possibilities, and further explorations into the molecular mechanisms underlying the 568 
central effects of B-GOS®, may reveal additional pathways through which gut bacteria influence 569 
brain function synergistically with the metabolites of this prebiotic. 570 
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Figure Legends 820 
 821 
Figure 1.The effects of B-GOS supplementation on NMDA iontophoresis in the prefrontal cortex. 822 
(A) Burst activities (top panel) and firing rate histograms showing the individual responses to the 823 
iontophoretic application of NMDA, in two representative cortical neurons from the water and the 824 
B-GOS group. Each top horizontal bar represents the pulsed current applied onto the neuron that 825 
induced transient neuronal activation.  (B) Cortical mean neuronal responses to iontophoretically 826 
applied NMDA at -5, -10 and -15 nA, in B-GOS-fed and control animals. There were no group x 827 
current interactions, but a significant effect of group where mean neuronal responses were greater 828 
in B-GOS rats compared to controls at all currents (nA). *p<0.05 compared to controls. n= 36 829 
(controls); n=44 (B-GOS). 830 
 831 
Figure 2.Cortical NMDA responses to HA-966 in B-GOS fed rats and controls.  (A) Individual 832 
activity traces (top panel) and firing rate histograms in response to iontophoretic applications of 833 
NMDA and HA-966, of two representative neurons from each group. The figure shows that HA-834 
966 more potently reduced the firing activation elicited by NMDA in the neuron from the control 835 
group compared to the neuron from the B-GOS fed rats. The NMDA pulses applied in the absence 836 
of HA-966 at the end of the experiment, demonstrated that neuronal responses were not influenced 837 
by preceding antagonist applications. (B) Burst activity traces (top panel) and mean responses to 838 
iontophoretically applied HA-966, at a fixed current of NMDA (typically between 5-10 nA, 839 
enough to produce a stable 4-5 HZ neuronal activation), decreased in both B-GOS and control 840 
rats. At -25nA of HA-966, the NMDA response was less efficiently reduced in B-GOS rats 841 
compared to controls. (C) Inhibitory dose response curves showing the effect of HA-966 on 842 
NMDA cortical responses in water and B-GOS rats.   *p<0.05, univariate analysis of group effect 843 
in 2-Way ANOVA (repeated measures); n=16/group 844 
25 
 
 845 
Figure 3. Neuronal responses to HA-966 alone and with iontophoretic application of NMDA and 846 
AMPA. (A) Representative traces (top panel) and neuronal response profile showing that 847 
application of HA-966 does not affect basal activity or subsequent NMDA responses after 848 
terminating its application. The latter confirms that HA-966 removal is rapid when its application 849 
is stopped. (B) Representative electrophysiological profile showing that HA-966 iontophoresis 850 
inhibits NMDA, but not AMPA, neuronal responses at 15nA. (C). High concentrations of HA-966 851 
applied to neurons (at similar current intensities used for inhibition of NMDA responses) does not 852 
affect neuronal activity in the cortex compared to controls (-3nA, n=17).  853 
 854 
Figure 4. Attentional set-shifting performance, body weight and fluid intake in water, BFS and B-855 
GOS rats.  (A) The intake of B-GOS reduced the number of trials required to complete the ED 856 
phase to criterion, compared to controls. The significant difference between the number of trials in 857 
ID and ED seen with control rats, was not observed for B-GOS fed animals. Rats supplemented 858 
with BFS required more trials to criterion for ED compared to animals that had received standard 859 
drinking water or B-GOS. (B) Body weight of BFS-fed rats were significantly greater than 860 
controls during attentional-set shifting tasks. Arrow indicates the start of food restriction to obtain 861 
85% of body weight for task performance. (C) Fluid intake by BFS-fed rats was significantly 862 
greater than controls 4 days after the start of supplementation and throughout the study. All data 863 
were analysed with 2-Way ANOVA (repeated measures). *p<0.05 compared to controls; 864 
#p<0.001 compared to ID phase; ∞ p<0.001 compared to BFS; n=12/group. 865 
 866 
Figure 5 Effect of B-GOS or glyceryl triacetate (GTA) supplementation on rat cortex GluN 867 
subunits, acetate concentrations and acetyl Co-A carboxylase (ACC) gene expression.  (A) 868 
Western blots demonstrated increased levels of cortical GluN2B subunits in B-GOS supplemented 869 
rats compared to controls. (B) A daily, 3 week administration of GTA (3g/kg) increased cortical 870 
GluN1 and GluN2B levels. (C) In B-GOS fed rats, plasma acetate levels and cortical ACC gene 871 
expression were increased relative to controls, whereas cortical acetate levels remained unaltered. 872 
(D) GTA supplementation elevated plasma, but not brain, acetate concentrations and ACC 873 
mRNA.  *p<0.05 compared to controls; n=8/group 874 
 875 
Figure 6 Effect of B-GOS or glyceryl triacetate (GTA) supplementation on rat cortex HDAC1-4 876 
mRNAs. (A) B-GOS supplementation did not affect the expression of HDAC genes. (B) A daily, 877 
3 week administration of GTA (3g/kg) increased cortical HDAC1 and HDAC2 mRNAs, but not 878 
HDAC3 and HDAC4. *p<0.05 compared to respective controls; n=8/group 879 
 880 
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